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ABSTRACT
Gestational trophoblastic diseases (GTD) includes a spectrum of diseases (tumor or tumor-like conditions) characterised by 
aberrant growth and development of the trophoblasts that may continue even beyond the end of pregnancy. It encompasses 
the benign trophoblastic disease (complete and partial moles), and the malignant trophoblastic diseases including the invasive 
mole (chorioadenoma destruens), choriocarcinoma, and Placental Site Trophoblastic Tumor (PSTT). This study was to 
determine the prevalence, risk factors, clinical presentation, diagnosis, treatment options and outcomes of GTD in Ahmadu 
Bello University Teaching Hospital (ABUTH) Zaria. A five-year retrospective study of patients with GTD managed at ABUTH, 
North-west Nigeria, from 1st January 2008 to 31st December, 2012 was undertaken. Data of all cases of GTD in the hospital 
over the 5 year period were obtained. The gynaecology ward and labour ward registers also provided information on the total 
number of gynaecological admissions and deliveries respectively. The data processing and analysis were carried out using 
the SPSS software version 16. The data obtained were expressed in percentages, means, and standard deviations. During 
the period of study there were 8,138 deliveries and 2,453 gynaecological admissions. There were 59 cases of GTD with 41 
having choriocarcinoma, 18 molar pregnancies and no case of invasive mole or PSTT. Out of the 41 case folders retrieved, 
23 were choriocarcinoma and 18 of molar pregnancies. The prevalence of GTD was 7.2 per 1000 deliveries (0.72% or 1 in 
138 deliveries) and constituted 2.4% of gynaecological admissions. Hydatidiform mole (HM) occurred in 1 in 452 deliveries 
and choriocarcinoma occurred in 1 in 198 deliveries. Ages ranged from 19-49 years with mean of 32.5+ 5.0 years. Most 
(66.7%) cases of HM were 19-29years while 60.9% of choriocarcinoma cases were 30-39years. Majority of cases were 
multiparous. The antecedent events predating choriocarcinoma were Hydatidiform mole (31.7%), abortions (29.3%) and 
2.4% followed term pregnancy. History of amenorrhea was present in all cases while vaginal bleeding occurred in 97.6%, 
pallor (87.8%), hyperemesis gravidarum (48.8%) and 4.9% came in shock. Consequently, common complications reported 
were haemorrhage (90.2%), anemia (87.8%) and shock (12.2%). Pregnancy test was positive in 90.2% of cases and serum 
beta hCG was done in 24.4% with more than half having a level >12,000miu/ml. All patients had pelvic ultrasound scan and 
snowstorm appearance occurred in 41% of benign GTD cases. Histology was used to confirm 56.1% cases of choriocarcinoma 
and 43.9% of molar gestation. Most (94.4%) of HM had suction evacuation while 95.6% of choriocarcinoma cases had 
chemotherapy, one case (2.4%) had Total Abdominal Hysterectomy. Contraception was used in 78% and common methods 
were male condom (41.5%) and 36.6% used combined oral contraceptive pills. Less than half (43.9%) had follow up for 6 
months and 9.8% were seen for more than a year. Eight patients had subsequent pregnancies and there was one death in 
the series giving a case fatality of 2.4%. Gestational trophoblastic disease is a significant source of maternal morbidity with 
increased risk of mortality from complications if not detected early and treated promptly.
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Introduction
Gestational trophoblastic disease (GTD) includes a spectrum 
of diseases (tumour or tumour‑like conditions) characterised 
by aberrant growth and development of the trophoblasts of 
placenta that may continue even after the end of pregnancy. 
GTD encompasses the benign trophoblastic disease (complete 
and partial moles) and the malignant trophoblastic diseases, 
including the invasive mole (chorioadenoma destruens), 
choriocarcinoma and placental‑site trophoblastic tumour (PSTT). 
They are composed of both syncytiotrophoblastic and 
cytotrophoblastic cells, with the exception of PSTT, which 
is derived from intermediate trophoblastic cells. In addition 
to being the first and only disseminated solid tumours that 
has proved to be highly curable by chemotherapy, they also 
produce a unique and characteristic tumour marker, human 
chorionic gonodotropin (HCG).[1‑7]
Complete mole, which is genetically 46XX, results from the 
fertilization of an empty ovum by a haploid sperm followed 
by duplication or Dispermy 46XY (fertilization of an empty 
ovum by 2 different sperms). On the other hand, partial 
mole is usually due to triploidy (69XXY, 69XXX, 69XYY).[8‑11] 
The hydatidiform mole (HM) is characterized pathologically 
by a bunch of grape‑like structures (complete mole has 
hydropic villi, trophoblastic hyperplasia and absent embryo 
whereas the partial mole has hydropic villi and fetal parts). 
The invasive mole is locally invasive and is usually diagnosed 
due to persistent HCG following approximately 5–10% of all 
molar pregnancies. Pathologically, molar changes are seen 
penetrating the myometrium on hysterectomy specimen or 
ultrasound scan. It is a cause of acute abdomen, haemorrhage 
and uterine perforation.[9‑14]
PSTT arises from the placental bed mostly from intermediate 
trophoblast, usually following a term pregnancy (1–3 years). 
It may be benign or malignant, secretes low amount of HCG 
but high human placental lactogen (HPL) and as such it is not 
chemosensitive. It rarely metastasizes beyond the uterus.[12‑14]
Fifty percent of choriocarcinomas follows HM, whereas 
abortion and term pregnancy contributes 25% each. It 
secretes large amount of HCG 100000–400000 units daily 
causing theca lutein cysts. It is pathologically characterized 
by haemorrhagic, necrotic tumour, invasive chorion with 
proliferation of syncytiotrophoblast and cytotrophoblast. It 
is metastatic but curable with chemotherapy. It is a source 
of significant morbidity with increased risk of mortality from 
complication, if not detected early and promptly treated.[12]
Studies have shown that GTD is source of significant morbidity 
with increased risk of mortality from complications, if not 
detected early and promptly treated. The incidence of GTDs, 
especially molar pregnancy, varies by geographic region. 
For instance, it is generally accepted that, in developing 
countries, the frequency is much higher.[1,2]
The incidence is higher in women younger than 20 years 
(teenagers) and older than 40 years of age (40–50 years).[1,3‑5] 
It is also higher in nulliparous women, in patients of low 
economic status and in women whose diets are deficient 
in protein, folic acid and carotene.[1] In the far east, figures 
of 1 in 500 individuals (Singapore), 1 in 294 (Japan) and 1 in 
314 (Iran) have been reported. In Ibadan, Nigeria, a high figure 
of 1 in 205 pregnancies has also been reported.[3]
Molar pregnancy usually presents in the 4th and 5th month 
of pregnancy and should be suspected in any woman with 
vaginal bleeding in the first half of pregnancy. This occurs 
in up to 92% of cases,[1] with passage of vesicles in 60%,[13] 
abdominal pain, hyperemesis gravidarum, hyperthyroidism 
or onset of pre‑eclampsia prior to 24 weeks of gestation. 
The absence of fetal heart tones, a uterus too large for the 
estimated gestational age and presence of theca lutein cysts 
on physical examination further support the diagnosis.[1,2,12] 
Honeycomb appearance on ultrasound scan was observed 
in 84% of the cases in Jos.[13] A high or rising serial beta‑HCG 
determination and histological examination are necessary to 
establish a firm diagnosis of GTD.[12]
According to the study by Rafindadi et al.[8] on the 
pathomorphology of molar gestation in Zaria (1995–2004), 
analysis of 56 cases showed complete HM in 34, partial HM 
in 20 and invasive mole in 2. The frequency of HM was 1 in 
612 deliveries. The mean age of the patients was 25.7 years, 
and their leading mode of presentation was vaginal bleeding 
during 11–18 weeks of gestation.
The treatment of different GTDs depends on the histological 
type. Suction evacuation is the most common form of 
management for HM.[9] Other modes of treatment include 
chemotherapy, hysterectomy and radiotherapy or a 
combination of these.[3,4]
Follow up is essential in all cases of GTD and is based on serial 
levels of HCG hormones, and studies have shown that many 
of the patients do not return for follow up.[4,5] The disease is of 
great interest because of its excellent prognosis, if diagnosed 
and treated on time, as well as the fact that the potential for 
child bearing can be preserved.[8] Approximately 20% of patients 
with complete HM would develop malignant sequelae.[5,12] This 
is lower (12–15%) in studies carried out in Jos, Nnewi and Ile‑Ife, 
which is attributed to poor follow‑up, which is as poor as 32%.[13] 
Contraception is advised to avoid pregnancy during follow up. 
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Mbamara et al. reported low contraceptive compliance among 
women being followed‑up for HM in Nnewi.[9]
Study justification
GTD is a significant source of maternal morbidity with 
increased risk of mortality from complications if not detected 
early and treated promptly.[1,2,7] It is hoped that the findings 
of this study will guide management of such cases in the 
future. It is also believed that the findings of this study will 
be used to recommend appropriate strategies to reduce the 
maternal morbidity and mortality arising from it.
Aim
This study was conducted to document the prevalence, risk 
factors, clinical presentations, diagnosis, treatment options 







A 5‑year retrospective study of patients with GTD managed at 
the ABUTH, Zaria, north‑west Nigeria from 1st January, 2008 
to 31st December, 2012 was undertaken. The names and 
hospital numbers of all cases of GTD in the hospital over the 
5‑year period were obtained from the gynaecology ward and 
operating theatre registers. The gynaecology ward and labour 
ward registers also provided information on the total number 
of gynaecological admissions and deliveries, respectively.
The variables considered included the maternal age at 
presentation, parity, marital status, as well as gestational age at 
presentation, risk factors, clinical presentations, investigation/
laboratory results, mode of treatment, post‑treatment 
contraception, follow‑up and the complications of GTD. 
These were extracted from the case file obtained from the 
records department. The data obtained were expressed 
as percentages, means and standard deviations. The data 
processing and analysis were carried out using the Statistical 
Package for the Social Sciences software version 16 (SPSS 
Inc. Released 2007, SPSS for Windows, Version 16.0. Chicago, 
SPSS Inc).
Inclusion criteria
All retrievable case files of cases of molar pregnancy managed 
within the study period.
Exclusion criteria
Those with incomplete records and irretrievable case files 
were excluded from the study.
Results were discussed and compared with the previous 
studies conducted elsewhere. Relevant conclusions were 
drawn from the results.
Results
During the study period, from 1st January, 2008 to 
31st December, 2012, there were a total of 59 (18 molar 
and 41 choriocarcinoma) cases of GTDs that were diagnosed 
and treated in ABUTH, Zaria. However, only 41 [18 (43.9%) 
molar and 23 (56.1%) choriocarcinoma] case files were 
retrieved from the Medical Records Department of the 
hospital, showing a retrieval rate of 69.5%. There was no case 
of invasive mole or placental trophoblastic tumour during 
the period under review. The total number of deliveries in 
this hospital during the same period was 8138, giving the 
incidence of GTDs as 0.72% or 1 in 138 deliveries or 7.2 per 
1000 deliveries (HM in 1 of 452 whereas choriocarcinoma in 
1 of 198 deliveries). Similarly, in the 5‑year period of study, 
there were 2453 gynaecological admissions, and hence, GTD 
constituted 2.4% of all gynecological admissions.
Table 1 shows the age distribution of the patients. Their ages 
ranged between 19 and 49 years, with the mean age being 
31.5 ± 5 years. The majority of the patients with HM (66.7%) 
were aged between 19 and 29 years whereas most of those 
with choriocarcinoma (60.9%) were aged between 30 and 
39 years. The parity distribution of the patients ranged 
between 0 and 10; this is shown in Table 2. The number of 
multiparous patients were the highest, 21 (51%) patients, 
followed by grandmultiparous 19 (46%) patients. There were 
2	 (4.9%)	 of	 para	≥10	 and	only	 1	 nullipara	 patient	 (2.4%).	
Table 3 shows that most respondents were Hausas (53.7%), 
Muslims (65.9%), and housewives (58.5%). Most cases of 
choriocarcinoma (16) 69.5% occurred in grandmultiparous 
women, whereas only 16.7% (3) of hydatidiform occurred in 
them. Most of the cases of choriocarcinoma had antecedent 
events with previous HM being 31.7%, followed by abortion 
in 29.3%, and only 2.4% followed term pregnancy. All the 
patients presented with amenorrhoea. However, in addition 
to amenorrhoea, the most common presenting symptom was 
abnormal vaginal bleeding, 40 (97.6%), followed by pallor 
36 (87.8%), large for gestational age, 31 (75.6%), dizziness 
26 (63.4%) and hyperemesis gravidarum 20 (48.8%). Only 
2 patients (4.9%) presented with shock. This is shown in 
Table 4.
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Table 5 shows the complications observed in patients 
with GTD. Haemorrhage was the most common 37 (90.2%) 
followed by anaemia in 36 (87.8%). The other complications 
included shock in 5 (12.2%) and hypertension 2 (4.9%). 
Laboratory results showed that 37 (90.2%) of all patients 
tested positive on pregnancy test. Only 10 (24.4%) had 
serum	beta‑HCG	and	50%	had	levels	≥12000	mIU/ml.	In	this	
study, all the patients underwent pelvic ultrasound scan. The 
typical snow storm appearance was described in 17 (41%) 
of the total cases. Histology confirmed 23 (56.1%) cases of 
choriocarcinoma and 18 (43.9%) of molar gestation, of which 
13 (31.7%) were complete moles; this is depicted in Table 6.
Regarding the treatment options given to patients with GTD, 
shown in Table 7, almost all the patients with HM [17 out of 
18 (94.4%)] had suction evacuation. Approximately 22 out of 
23 (95.6%) patients with choriocarcinoma had chemotherapy, 
whereas only one of the total cases (2.4%) had hysterectomy. 
Majority of those who were followed up 32 (78.0%) used 
contraception following treatment. Barrier method using 
male condom was the most common contraceptive method 
used in 17 (41.5%) cases followed by combined oral 
contraceptives in 15 (36.6%).
Table 4: Clinical manifestation of patients with gestational 
trophoblastic disease (GTD) seen in Abuth, Zaria over a 5‑year 
period
Presenting complaints Frequency Percentage
Amenorrhoea 41 100
Abnormal vaginal bleeding 40 97.6
Pallor 36 87.8
Large Gestational Age 31 75.6
Hyperemesis gravidarum 20 48.8
Dizziness 26 63.4
Ovarian Enlargement 2 4.9
Urethral Nodule 2 4.9
Table 5: Clinical complication of patients with gestational 








Hyperthyroidism/ Thyrotoxicosis Nil Nil
Table 1: Age distribution of patients with gestational 
trophoblastic disease (GTD) seen in Abuth, Zaria over a 5‑year 
period
Age (years) Benign GTD, n (%) Malignant GTD, n (%)
19‑29 12 (66.7%) 6 (26.1%)
30‑39 5 (27.8%) 14 (60.9%)
40‑49 1 (5.5%) 3 (13.0%)
Total 18 (100%) 23 (100%)
Table 2: Parity distribution of patients with gestational 
trophoblastic disease (GTD) seen in Abuth, Zaria over a 5‑year 
period
Parity Molar gestation Choriocarcinoma Total
0 1 0 1
2.4% 0.0% 2.4%
1 5 1 6
12.2% 2.4% 14.6%
2 2 0 2
4.8% 0.0% 4.9%
3 6 3 9
14.6% 7.3% 22.0%
4 1 3 4
2.4% 7.3% 9.8%
5 1 5 6
2.4% 12.2% 14.6%
6 1 6 7
2.4% 14.6% 17.1%
7 1 3 4
2.4% 7.3% 9.8%


























Not indicated 1 2.4
Trader 5 12.2
Civil servant 4 9.8
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The follow‑up of patients following treatment is shown 
in Table 8. Only 18 (43.9%) of the patients had complete 
post‑treatment follow‑up for 6 to 12 months, and only 
4 cases (9.8%) were followed up for over 1 year, whereas 
2 (4.9%) cases were lost to follow‑up. Eight of the patients 
had subsequent pregnancies. There was one maternal death 
during the period under review, giving a case fatality rate 
of 2.4%.
Discussion
The prevalence of 7.2 per 1000 deliveries in this study shows 
that GTD is quite common in our environment. This is higher 
than 4.7/1000 deliveries reported in Nnewi[10] and 4.06 in 
Onitsha[15] both in south‑east Nigeria. This increased high 
prevalence of GTD in our centre may be due to the status of 
a teaching hospital as well as a referral centre from various 
clinics both private and public. The HM prevalence rate of 
1 in 452 deliveries found in this study is similar to 1 in 500 
in Singapore but lower than 1 in 357 from Jos, Nigeria.[3,13] 
This study noted higher incidence of choriocarcinoma than 
HM. This is similar to the finding in Nnewi, but differs from 
other studies with higher incidence of HM.[10,13] This may 
be attributable to the fact that many patients with HM end 
up at peripheral centres where suction evacuation was 
enough treatment for them, leaving those with persistent 
symptoms (mostly choriocarcinoma) to present to our centre, 
thereby tilting the ratio of patients with GTD in favour of 
choriocarcinoma.
Maternal age has been reported to influence the risk of 
GTD with the prevalence being increased in women lower 
than 20 years and above 40 years of age.[1,3,5] The findings 
of the study do not support this because women between 
30 and 38 years of age formed the majority of the patients. 
This, however, conforms with the experience of other 
researchers.[2,11,13] In addition, most of the patients were 
multiparous, 21 (51%) as found in some studies, but at 
variance with those of other researcehrs.[4,5,13] This lends 
credence to the suggestion that parity per se may not be 
an independent factor for the epidemiology of GTD.[10] As 
expected, choriocarcinoma follows an antecedent event. In 
this study, most of the cases of choriocarcinoma occurred 
following previous HM in 31.7%, abortion 29.3% and only 
2.4% followed term pregnancy.[21,22,24]
All the patients in this review presented with amenorrhoea 
similar to the results of previous studies in the literature.[1,10,13‑23] 
This reflects the fact that there is a need for early booking 
for every patient who ever suspects or confirms that she is 
pregnant. In addition, there should be an evaluation of all 
patients with history of amenorrhoea, because with routine 
first trimester ultrasonography, a significant proportion 
of patients can be identified,[14,15] although they may be 
asymptomatic at the time of diagnosis.[2]
In addition to amenorrhoea, this study revealed that the 
most common clinical manifestation of molar pregnancy 
was abnormal vaginal bleeding. This occurred in more than 
97.6% of cases. This agrees fully with documentations in 
the literature where more than 90% of patients with molar 
pregnancies present with abnormal uterine bleeding, usually 
during the first trimester.[2,3,12,20,23]
In addition, a “large for gestational age” uterus was observed 
in more than 70% of the cases with GTD seen in our centre. 
This finding was corroborated by the observation in the 
literature where approximately half of the patients with 
molar pregnancy have uterine size that are greater than the 
appropriate size for their gestational age.[3,20,23]
Regarding the complications associated with molar 
pregnancies, this study has demonstrated that haemorrhage 
Table 6: Histological variants of patients with gestational 
trophoblastic disease (GTD) seen in Abuth, Zaria over a 5‑year 
period
Histology Frequency Percent
Molar gestation complete 13 31.7
Molar gestation partial 5 12.2
Choriocarcinoma 23 56.1
Total 41 100.0
Table 7: Mode of treatment of patients with gestational 
trophoblastic disease (GTD) seen in Abuth, Zaria
Treatment Benign GTD Malignant GTD Total
Suction evacuation only 17 0 17
41.5% 0.0% 41.5%
Hysterectomy only 0 1 1
0.0% 2.4% 2.4%
Chemotherapy 1 22 23
2.4% 53.7% 56.1%
Total 18 23 41
43.9% 56.1% 100.0%
Table 8: Follow‑up of patients with molar pregnancy seen in 
Abuth, Zaria
Duration Frequency Percentage
Not indicated 1 2.4
0‑1 month 2 4.9
1‑6 months 14 34.1
6‑12 months 18 43.9
>12 months 4 9.8
Lost to follow up 2 4.9
Total 41 100.0
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(90.2%) was the most common complication, followed by 
anaemia and shock. These findings are similar to the study 
in Onitsha where haemorrhage was the most common 
complication.[15] Anaemia could result from late presentation 
following abnormal uterine bleeding or late booking of 
so‑called ongoing pregnancy. It could also result from severe 
haemorrhage occurring during the evacuation process or 
as a result of post‑evacuation chemotherapy.[2,3] The shock 
observed in these patients could also be as a result of the 
haemorrhage.
This study has also demonstrated that all the cases of GTD 
reviewed were diagnosed by pelvic ultrasound scan. Therefore, 
the importance of ultrasound in the management of patient 
with suspected GTD cannot be over‑emphasised. As reported 
earlier, an ultrasound scan should be obtained in any patient 
who presents with vaginal bleeding in the first half of pregnancy 
and has a uterus greater than 12 weeks gestational size.[3] 
However, even when the uterus is appropriate for gestational 
age, ultrasound scan can be the key in differentiating factor 
between a normal pregnancy and a GTD.[3]
Another important investigation which is both essential in 
the diagnosis and management of GTD is serum beta‑HCG 
determination by radioimmunoassay. It measures the 
beta‑HCG which is more sensitive and specific than urinary 
beta‑HCG.[1,3] However, this was done in only 24.4% of the 
cases (who could afford a private laboratory due to lack of 
facilities for radioimmunoassay where many of these cases 
were managed). More than 50% of them had levels greater 
than 12000 mIU/ml. The rest of the patients had urinary 
beta‑HCG determined by pregnancy test in “neat and dilution” 
and 90.2% had a positive test.
In this study, suction evacuation was employed in the 
management of HM in our centre and was done in more than 
94% of cases. This finding was in agreement to the Royal College 
of Obstetrician and Gynaecologists’ practical guidelines on 
the management of complete molar pregnancy.[1,2,12,27] Suction 
evacuation is safe, rapid and effective in nearly all cases of 
HM.[2,3,20‑26] In our centre, as revealed by this study, over 95% 
of choriocarcinoma were managed by chemotherapy. Only 
1 (2.4%) case had hysterectomy. Hysterectomy remains an 
option for good surgical candidates who are not desirous of 
future pregnancies. It is also done for older women with HM 
who are more likely to develop malignant sequelae.[3,13] This 
patient had hysterectomy because she had an uncontrollable 
haemorrhage at presentation.
It was noted that the majority of the patients (78.0%) received 
post‑treatment contraception and barrier contraception, 
with male condoms as the most common contraceptive 
method used by the study patients. These findings differ 
from those presented in other studies.[9,10,13] After completion 
of the treatment, the use of contraceptive is recommended 
so that pregnancy is avoided for 12 months to minimize 
the confusion over disease relapse from HCG produced in 
pregnancy.[1,2,6]
In this review, only 43.9% of the patients had complete 
post‑treatment follow‑up for at least 6 months and only 
9.8% cases were followed‑up for more than 1 year. It is 
recommended that patients should be seen initially weekly, 
monthly and then every 3 months intervals for a total of 
one year.[2,3,6] A follow‑up period longer than one year is not 
necessary for benign GTD.[2,16‑19,27] During each visit, a clinical 
examination should be carried out. The serum B‑subunit 
HCG assay is performed,[8,17‑19] and a chest X‑ray is repeated 
if indicated.[2,3]
The case fatality rate in our study was 2.4%. This is high 
when compared with other studies where there were no 
recorded maternal deaths.[12,14] In this study, the maternal 
death occurred in patients who had very severe shock and 
had irreversible shock at presentation and after evacuation.
Conclusion
There was a high prevalence of GTD in our tertiary health 
institution during the period of study. It is an important cause 
of maternal morbidity and mortality in our centre. There is 
need for early recognition, timely referral and prompt and 
proper management of this condition. Adequate follow‑up 
of the patients is mandatory.
One of the limitations of this study was that the incidence of 
subsequent pregnancies after complete treatment of molar 
pregnancies was not studied. Moreover, it was a retrospective 
study with attendant set‑back of incomplete information. 
Finally, there was poor follow‑up and a lot of case files could 
not be retrieved.
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